Literature DB >> 26345274

Severe CNS involvement in WWOX mutations: Description of five new cases.

Brahim Tabarki1, Amal AlHashem2, Saad AlShahwan1, Fowzan S Alkuraya3,4, Satyanarayana Gedela5, Giulio Zuccoli6.   

Abstract

Recently, mutations in WWOX have been identified in the setting of central nervous system (CNS) disorders, highlighting a previously unrevealed role of this gene in the normal development and function of the CNS. In this report, we add five patients from two seemingly unrelated families presenting with a primarily neurological phenotype. All the children were product of consanguineous marriages. Whole exome sequencing revealed the same homozygous mutation (NM_016373.3:c.606-1G>A) of WWOX in all five patients. All patients and carriers in the family share the same haplotype indicating the families are in fact related to one another. The clinical presentation included progressive microcephaly, early onset of spasticity in the first 3 months of life, intractable epilepsy, severe failure to thrive, and profound developmental delay. Retinopathy was observed in two patients. All five patients died before their third birthday. Neuroimaging showed extensive neurodegeneration characterized by periventricular white matter volume loss and atrophy of the corpus callosum. Additional degeneration selectively affecting the mediodorsal nucleus of the thalamus was observed in one patient. Our findings in five new patients affected by WWOX mutation with early infantile phenotype confirm the features of the disease represented by early infantile epileptic encephalopathy. We suggest that neuroimaging in these patients reveals a characteristic pattern of neurodegeneration in which the cerebellum is spared that could help with early diagnosis in the appropriate clinical setting.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  epileptic encephalopathy; microcephaly; spasticity

Mesh:

Substances:

Year:  2015        PMID: 26345274     DOI: 10.1002/ajmg.a.37363

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

1.  Novel mutations in WWOX, RARS2, and C10orf2 genes in consanguineous Arab families with intellectual disability.

Authors:  Asem M Alkhateeb; Samah K Aburahma; Wesal Habbab; I Richard Thompson
Journal:  Metab Brain Dis       Date:  2016-04-28       Impact factor: 3.584

Review 2.  Imaging structural and functional brain development in early childhood.

Authors:  John H Gilmore; Rebecca C Knickmeyer; Wei Gao
Journal:  Nat Rev Neurosci       Date:  2018-02-16       Impact factor: 34.870

3.  A novel missense variant in the SDR domain of the WWOX gene leads to complete loss of WWOX protein with early-onset epileptic encephalopathy and severe developmental delay.

Authors:  Jessika Johannsen; Fanny Kortüm; Georg Rosenberger; Kristin Bokelmann; Markus A Schirmer; Jonas Denecke; René Santer
Journal:  Neurogenetics       Date:  2018-05-28       Impact factor: 2.660

4.  WWOX inhibition by Zfra1-31 restores mitochondrial homeostasis and viability of neuronal cells exposed to high glucose.

Authors:  Cristina Carvalho; Sónia C Correia; Raquel Seiça; Paula I Moreira
Journal:  Cell Mol Life Sci       Date:  2022-08-19       Impact factor: 9.207

5.  Wwox deletion leads to reduced GABA-ergic inhibitory interneuron numbers and activation of microglia and astrocytes in mouse hippocampus.

Authors:  Tabish Hussain; Hyunsuk Kil; Bharathi Hattiangady; Jaeho Lee; Maheedhar Kodali; Bing Shuai; Sahithi Attaluri; Yoko Takata; Jianjun Shen; Martin C Abba; Ashok K Shetty; C Marcelo Aldaz
Journal:  Neurobiol Dis       Date:  2018-10-02       Impact factor: 5.996

6.  Early infantile-onset epileptic encephalopathy 28 due to a homozygous microdeletion involving the WWOX gene in a region of uniparental disomy.

Authors:  Mariska Davids; Thomas Markello; Lynne A Wolfe; Xenia Chepa-Lotrea; Cynthia J Tifft; William A Gahl; May Christine V Malicdan
Journal:  Hum Mutat       Date:  2018-11-18       Impact factor: 4.878

Review 7.  Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells.

Authors:  Muhannad Abu-Remaileh; Emma Joy-Dodson; Ora Schueler-Furman; Rami I Aqeilan
Journal:  J Biol Chem       Date:  2015-10-23       Impact factor: 5.157

8.  Zfra restores memory deficits in Alzheimer's disease triple-transgenic mice by blocking aggregation of TRAPPC6AΔ, SH3GLB2, tau, and amyloid β, and inflammatory NF-κB activation.

Authors:  Ming-Hui Lee; Yao-Hsiang Shih; Sing-Ru Lin; Jean-Yun Chang; Yu-Hao Lin; Chun-I Sze; Yu-Min Kuo; Nan-Shan Chang
Journal:  Alzheimers Dement (N Y)       Date:  2017-03-06

Review 9.  Modeling WWOX Loss of Function in vivo: What Have We Learned?

Authors:  Mayur Tanna; Rami I Aqeilan
Journal:  Front Oncol       Date:  2018-10-10       Impact factor: 6.244

Review 10.  The phenotypic spectrum of WWOX-related disorders: 20 additional cases of WOREE syndrome and review of the literature.

Authors:  Juliette Piard; Lara Hawkes; Mathieu Milh; Laurent Villard; Renato Borgatti; Romina Romaniello; Melanie Fradin; Yline Capri; Delphine Héron; Marie-Christine Nougues; Caroline Nava; Oana Tarta Arsene; Debbie Shears; John Taylor; Alistair Pagnamenta; Jenny C Taylor; Yoshimi Sogawa; Diana Johnson; Helen Firth; Pradeep Vasudevan; Gabriela Jones; Marie-Ange Nguyen-Morel; Tiffany Busa; Agathe Roubertie; Myrthe van den Born; Elise Brischoux-Boucher; Michel Koenig; Cyril Mignot; Usha Kini; Christophe Philippe
Journal:  Genet Med       Date:  2018-10-25       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.